Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PPARA gene and phenprocoumon: a new predictor of response variability.

Pharmacogenetics and genomics - 1 Feb 2015

Botton Mariana R, Bandinelli Eliane, Leiria Tiago L L, Rohde Luis E P, Hutz Mara H

Abstract excerpt

Phenprocoumon is an anticoagulant used for thromboembolic disorder prophylaxis metabolized mainly by CYP3A4. However, polymorphisms in this gene did not explain the observed variability. PPARA (peroxisome proliferator-activated receptor-α) is a nuclear receptor that, among others, influences CYP3A4 gene expression. The aim of this study was to determine whether PPARA gene polymorphisms and the CYP3A4*22 allele...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Thromboembolism
Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticoagulants

Share to Biomarkers, Pharmacological

Share to Dose-Response Relationship, Drug

Share to Gene Frequency

Share to PPAR alpha

Source

Identifiers

PMID: 25461249
DOI: 10.1097/FPC.0000000000000109

Genes

PPARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

PPARA gene and phenprocoumon: a new predictor of response variability.PMID 25461249Read ↗

A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms.Semantic proximity Read ↗

PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.Semantic proximity Read ↗

VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.Semantic proximity Read ↗

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.Semantic proximity Read ↗

Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.Semantic proximity Read ↗

Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose.Semantic proximity Read ↗

Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing.Semantic proximity Read ↗

Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.Semantic proximity Read ↗

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.Semantic proximity Read ↗

Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.